Expertise in
4
conditions

Anna V. Tinker

Vancouver, BC, CA 
Expertise in
4
conditions
Vancouver, BC, CA 

Overview

Anna Tinker practices practicing medicine in Vancouver, Canada.

Ms. Tinker is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Oophorectomy, and Vulvectomy.

She is actively involved in clinical research, co-authoring 105 peer reviewed articles and participating in 7 clinical trials.

Gender

Female

Locations

Vancouver, BC V6H3N1, Canada
Other Locations
Montreal, QC, Canada
BC, Canada
British Columbia Cancer Surrey
Surrey, BC, Canada
Victoria, BC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Phase II, Open Label Study of the Poly(ADP-ribose) Polymerase Inhibitor Niraparib in Monotherapy or in Combination With Anti-PD1 Inhibitor TSR-042 in Recurrent Endometrial Cancer
A Phase II, Open Label Study of the Poly(ADP-ribose) Polymerase Inhibitor Niraparib in Monotherapy or in Combination With Anti-PD1 Inhibitor TSR-042 in Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 23, 2026
Intervention Type: Drug
Study Drugs: Niraparib, TSR-042
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 24, 2026
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Study Phase: Phase 3
A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)
A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)
Enrollment Status: Terminated
Publish Date: February 20, 2024
Intervention Type: Drug, Radiation
Study Drugs: Adavosertib, Cisplatin
Study Phase: Phase 1
A Retrospective/Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours
A Retrospective/Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours
Enrollment Status: Completed
Publish Date: January 10, 2023
Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer
Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer
Enrollment Status: Terminated
Publish Date: February 17, 2022
Intervention Type: Drug, Procedure
Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas
Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas
Enrollment Status: Completed
Publish Date: December 13, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

105 Total Publications

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.
Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.
Journal: Current oncology (Toronto, Ont.)
Published: April 04, 2026

Frequently Asked Questions about Anna V. Tinker

Is Anna V. Tinker a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Anna V. Tinker is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Anna V. Tinker participate in research or clinical trials?

Yes. Anna V. Tinker has published 105 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Anna V. Tinker's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Tinker's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile